<p><strong>Special warnings</strong>: Patients with rare hereditary problems of galactose intolerance, lactose deficiency or glucose-galactose malabsorption should not take this medicine.<br />
<br />
<strong>Myalgia/myopathy</strong>: Patients should be advised to report unexplained muscle pain, tenderness or weakness immediately.<br />
<br />
<strong>Patients with impaired hepatic function</strong>: Periodic hepatic function tests are recommended (every 3 months for the first 12 months of treatment). Ciprofbrate treatment should be discontinued in case of increased AST and ALT levels to more than 3 times the upper limit of normal or if cholestatic liver injury is evidenced.</p>